145 related articles for article (PubMed ID: 2426299)
21. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
22. Circulating bradykinin-like immunoreactivity and the pentagastrin-induced carcinoid flush.
Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
Clin Endocrinol (Oxf); 1988 Aug; 29(2):141-51. PubMed ID: 3248356
[TBL] [Abstract][Full Text] [Related]
23. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.
Feldman JM; O'Dorisio TM
Am J Med; 1986 Dec; 81(6B):41-8. PubMed ID: 2432780
[TBL] [Abstract][Full Text] [Related]
24. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients.
van Dijk SC; de Herder WW; Kwekkeboom DJ; Zillikens MC; Feelders RA; van Schaik RH; van Driel M; van Leeuwen JP
Bone; 2012 Jun; 50(6):1260-5. PubMed ID: 22425693
[TBL] [Abstract][Full Text] [Related]
25. Pseudocarcinoid syndrome associated with hypogonadism and response to testosterone therapy.
Shakir KM; Jasser MZ; Yoshihashi AK; Drake AJ; Eisold JF
Mayo Clin Proc; 1996 Dec; 71(12):1145-9. PubMed ID: 8945484
[TBL] [Abstract][Full Text] [Related]
26. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
27. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites.
Matuchansky C; Launay JM
Gastroenterology; 1995 Mar; 108(3):743-51. PubMed ID: 7533112
[TBL] [Abstract][Full Text] [Related]
28. Measurement and partial characterization of the multiple forms of neurokinin A-like immunoreactivity in carcinoid tumours.
Conlon JM; Deacon CF; Richter G; Schmidt WE; Stöckmann F; Creutzfeldt W
Regul Pept; 1986 Jan; 13(2):183-96. PubMed ID: 3006157
[TBL] [Abstract][Full Text] [Related]
29. Neuropeptide K-(1-24)-peptide: storage and release by carcinoid tumors.
Conlon JM; Deacon CF; Grimelius L; Cedermark B; Murphy RF; Thim L; Creutzfeldt W
Peptides; 1988; 9(4):859-66. PubMed ID: 3226960
[TBL] [Abstract][Full Text] [Related]
30. Tachykinins (substance P, neurokinin A, neuropeptide K, and neurokinin B) in the cerebral circulation: vasomotor responses in vitro and in situ.
Jansen I; Alafaci C; McCulloch J; Uddman R; Edvinsson L
J Cereb Blood Flow Metab; 1991 Jul; 11(4):567-75. PubMed ID: 1711051
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical distribution, biochemical characterization, and biological action of tachykinins in the frog adrenal gland.
Leboulenger F; Vaglini L; Conlon JM; Homo-Delarche F; Wang Y; Kerdelhue B; Pelletier G; Vaudry H
Endocrinology; 1993 Nov; 133(5):1999-2008. PubMed ID: 7691584
[TBL] [Abstract][Full Text] [Related]
32. Tachykinin production by carcinoid tumours in culture.
Norheim I; Wilander E; Oberg K; Theodorsson-Norheim E; Lundqvist ML; Lindgren P; Bergh J
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):689-95. PubMed ID: 3477459
[TBL] [Abstract][Full Text] [Related]
33. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
34. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
[TBL] [Abstract][Full Text] [Related]
35. Bradykinin in carcinoid syndrome.
Gustafsen J; Boesby S; Nielsen F; Giese J
Gut; 1987 Nov; 28(11):1417-9. PubMed ID: 3428666
[TBL] [Abstract][Full Text] [Related]
36. Expression of tachykinins by ileal and lung carcinoid tumors assessed by combined in situ hybridization, immunocytochemistry, and radioimmunoassay.
Bishop AE; Hamid QA; Adams C; Bretherton-Watt D; Jones PM; Denny P; Stamp GW; Hurt RL; Grimelius L; Harmar AJ
Cancer; 1989 Mar; 63(6):1129-37. PubMed ID: 2645037
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease.
Carling RS; Degg TJ; Allen KR; Bax ND; Barth JH
Ann Clin Biochem; 2002 Nov; 39(Pt 6):577-82. PubMed ID: 12564839
[TBL] [Abstract][Full Text] [Related]
38. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
Ruszniewski P; Ducreux M; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Bernades P; Rougier P
Gut; 1996 Aug; 39(2):279-83. PubMed ID: 8977344
[TBL] [Abstract][Full Text] [Related]
39. The pentagastrin test in the diagnosis of the carcinoid syndrome.
Ahlman H; Dahlström A; Grönstad K; Jaffe BM; Nilsson O; Oberg K
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S86-8. PubMed ID: 2412067
[TBL] [Abstract][Full Text] [Related]
40. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
